American Univesity of Beirut

​​​​

• Commentary on the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
  El-Hajj Fuleihan G*, Drake MT.  Metabolism 2023 Jun;143:155553.doi: 10.1016/j.metabol.2023.155553.
  
• ​​​​​​​​​Metabolism, Clinical and Experimental: Seventy Years Young and Growing.​
  Polyzos​ S, Hill M, El-Hajj Fuleihan G, Gnudi L, Kim YB, Larsson S, Masuzaki H, Matarese G, Sanoudou D, Tena Sempere M, Mantzoros C. Metabolism 2022; 137:155333.
  
• Reply to vitamin D deficiency in covid-19: mixing up cause and consequence. ​
  Chakhtoura M, El Hajj Fuleihan G. Metabolism 2021​; 115:154462.
• Myths and facts on vitamin D amidst the covid-19 pandemic.​​
  Chakhtoura M, Napoli N, El Hajj Fuleihan G. Metabolism Clinical and Experimental  2020; 109:154276.
• Building bridges to address the osteoporosis crisis.
  El-Hajj Fuleihan G. J Clin Endocrinol Metab 2020 ;105(4):1292-1293.
• Geographical and ethnic disparities in osteoporotic fractures.​
  Cauley JA, Chalhoub D, Kassem AM, El-Hajj Fuleihan G. Nat. Rev. Endocrinol 2014; 10:338-351.
• Mechanisms of diabetes mellitus-induced bone fragility.
  Napoli N, Chandran M, Pierroz D, Abrahamsen B, Schwartz AV, Ferrari S. The authors acknowledge the support of the other members of the CSA IOF bone and diabetes working group: Akesson K, Ardawi MSM, Cooper C, Eastell R, El-Hajj Fuleihan G, Hough S, Josse R, Kendler D, Kraenzlin M, Leslie W, Massi Benedetti M, Mithal A, Suzuki A. Invited Review. Nrendo 2017; 3.
• Can the sunshine vitamin melt the fat?​​​​​
  El-Hajj Fuleihan G. Metabolism 2012; 61:603-610.
• Hypovitaminosis D in Developing Countries—Prevalence, Risk Factors and Outcomes.
  Arabi A, El Rassi R and El-Hajj Fuleihan G. Nat Rev Endocrinol 2010; 6:550-561.
• Endocrine and Musculoskeletal abnormalities in patients with Down Syndrome.
  Hawli Y, Nasrallah M, El-Hajj Fuleihan G. Nat Rev Endocrinol. 2009; 5(6):327-334.
• How effective is risedronate in preventing bone loss in patients on high dose steroids? practice point commentary.
  Asma A, El-Hajj Fuleihan G. Nature Clinical Practice Endocrinology 2008; 4(10):540-541.
• Hyperparathyroidism: time to reconsider current clinical decision paradigms?​
  El-Hajj Fuleihan G. Editorial. J Clin Endocrinol Metab 2008; 93(9):3302-3304.
• Tibolone and the promise of ideal hormone replacement therapy.
  El-Hajj Fuleihan G. editorial. New Engl J Med 2008; 359(7):753-755.​
  
• Leptin effect on bone: is it ethnic specific?
  Arabi A. J Lab Clin Med. 2005;146(1):7-8.
• Strontium ranelate: a novel therapy for osteoporosis or a permutation of the same?
  El-Hajj Fuleihan G. editorial. N Engl J Med 2004; 350:504-506.
• Tissue-specific estrogens—the promise for the future.​​
  ​El-Hajj Fuleihan G. editorial. N Engl J Med 1997; 337:1686-1687.​​